AstraZeneca has inked a global license collaboration with Targacept for the latter’s experimental antidepressant, TC-5214, in a deal valued at US$1.24 B. This new deal deepens the relationship between the two companies who were already working on developments focused on cognitive disorders from a previous agreement.